Imcivree Approved for Weight Management in Bardet-Biedl Syndrome
Imcivree is a melanocortin 4 receptor (MC4R) agonist that re-establishes MC4 receptor pathway activity to reduce hunger and promote weight loss.
Imcivree is a melanocortin 4 receptor (MC4R) agonist that re-establishes MC4 receptor pathway activity to reduce hunger and promote weight loss.
Author reviews the pathophysiology of obesity including the role of incretin hormones and the mechanism of action, efficacy, and safety of GLP-1 receptor agonists as antiobesity medications.
A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.
Adolescent obesity is correlated with both adult-onset type 1 diabetes and type 2 diabetes.
Investigators examined the effect of obesity on microvascular and macrovascular complications among patients with type 1 or type 2 diabetes.
A team of investigators evaluated the success of a time-restricted eating intervention among individuals at increased risk of developing type 2 diabetes.
While food insecurity is a leading public health issue, research shows that nutrition security may be a better target for disease prevention strategies.
The ENGAGE-2 Mechanistic Pilot trial was a randomized clinical trial conducted at the University of Illinois at Chicago and Stanford University between 2019 and 2020.
The aim of the study was to identify individuals with food insecurity and establish processes to refer patients and families to federal and community resources.
The SURMOUNT-1 trial evaluated tirzepatide as an adjunct to a reduced-calorie diet and increased physical activity in adults without type 2 diabetes who have obesity or are overweight.